• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Menu
    • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy

    Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

    Explore Muscle

    • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.

    Explore our Science

    • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories

    We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.

    Read their Stories

    • Company
    • Leadership Team
    • Careers
    • Contact Us

    Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.

    Learn More

    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
Home Company Leadership Team R. Michael Carruthers

R. Michael Carruthers

Chief Financial Officer

Michael Carruthers has served as our Chief Financial Officer since September 2020. Mr. Carruthers has over 20 years of experience serving as Chief Financial Officer for publicly-traded biopharmaceutical companies, with extensive experience across corporate finance and strategic planning including IPOs, secondary offerings and M&A transactions. Most recently, Mr. Carruthers consulted as Chief Financial Officer for several private and public companies. Previously, Mr. Carruthers served as Interim President of Nivalis Therapeutics, a publicly traded company acquired by Alpine Immune Sciences, in 2017 and Chief Financial Officer and Secretary from 2015 to 2017. From 1998 to 2015, he served as Chief Financial Officer for Array BioPharma Inc., a publicly traded company acquired by Pfizer Inc. Prior to this, he served as Chief Financial Officer of Sievers Instruments, Treasurer and Controller for the Waukesha division of Dover Corporation and Accountant with Coopers & Lybrand. Mr. Carruthers serves on the boards of Elevation Oncology (Nasdaq: ELEV) and OnKure, Inc., . Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.

  • Meet our leadership team
  • Meet our board of directors

Footer

Edgewise Therapeutics
  • Disease Areas
  • Science & Pipeline
  • Patients & Families
  • Company
  • Investors & News

Deep knowledge of integrated 
muscle physiology

Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

Explore our Science

2025 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy
  • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations
  • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts